Patent
Disclosed herein is a UV mutagenesis produced new Streptomyces spororaveus strain SC263 that exhibits an increased thermostability of the antibiotic produced, which shows antibiotic activity against bacteria and fungi. Also provided are the antibiotic produced by SC263 and a composition thereof for treatment of bacterial and fungal infections. The antibiotic has a very high molecular weight, which is suitable for topical administration.
1 . A Streptomyces spororaveus strain SC263 deposited with the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 34277.
2 . A composition comprising the strain SC263 of claim 1 .
3 . The composition of claim 2 , wherein the Streptomyces spororaveus strain SC263 is viable.
4 . The composition of claim 2 , wherein the Streptomyces spororaveus strain SC263 is inactivated.
5 . An antibiotic produced by the strain SC263 of claim 1 .
6 . The antibiotic of claim 5 , wherein the antibiotic exhibits an apparent molecular weight of larger than 5 kDa measured by membrane-filtration concentration.
7 . The antibiotic of claim 5 , wherein the antibiotic exhibits an apparent molecular weight of 10 kDa to 100 kDa, measured by membrane-filtration concentration.
8 . The antibiotic of claim 5 , wherein the antibiotic is effective against fungi.
9 . The antibiotic of claim 5 , wherein the antibiotic is effective against Gram-positive bacteria.
10 . An antimicrobial composition or pharmaceutical composition comprising the antibiotic of claim 5 and a pharmaceutically acceptable carrier.
11 . An antimicrobial composition or pharmaceutical composition comprising the strain SC263 of claim 1 , and a pharmaceutically acceptable carrier.
12 . The composition or pharmaceutical composition of claim 10 , which is effective for treatment of a fungal infection.
13 . The composition or pharmaceutical composition of claim 10 , which is effective for treatment of a bacterial infection.
14 . The composition or pharmaceutical composition of claim 11 , which is effective for treatment of a fungal infection.
15 . The composition or pharmaceutical composition of claim 11 , which is effective for treatment of a bacterial infection.
16 . The composition or pharmaceutical composition of claim 13 , which is effective against Gram-positive bacteria.
17 . The composition or pharmaceutical composition of claim 15 , which is effective against Gram-positive bacteria.
18 . The composition or pharmaceutical composition of claim 10 , which is administered topically.
19 . The composition or pharmaceutical composition of claim 11 , which is administered topically.